GlassScriptPhysician profile
Syed Rizvi
NPI 1801089289
$17,181.34
in general payments reported to CMS, 2019-2025
16 companies · $309 in 2025
The $309 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,114 · 2020: $1,278 · 2023: $8,928 · 2024: $553 · 2025: $309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,514 · Food and Beverage: $1,065 · Travel and Lodging: $211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,513.75 |
| Food and Beverage | $1,064.95 |
| Travel and Lodging | $211.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $8,914.65 | 2023 | Evobrutinib |
| Otsuka America Pharmaceutical, INC. | $6,259.65 | 2019-2020 | |
| Stryker Corporation | $717.53 | 2024-2025 | Infinity Adaptis, Augment Injectable, Anchorage |
| Neurocrine Biosciences, INC. | $281.67 | 2019-2020 | |
| Alkermes, INC. | $242.78 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $170.37 | 2019-2020 | |
| Lundbeck LLC | $149.03 | 2019 | |
| Treace Medical Concepts, INC. | $144.45 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $85.32 | 2019 | |
| Sunovion Pharmaceuticals INC. | $80.14 | 2019-2020 | |
| Allergan, INC. | $57.00 | 2019-2020 | |
| Indivior INC. | $25.02 | 2019 | |
| Vanda Pharmaceuticals INC. | $15.00 | 2020 | |
| Acadia Pharmaceuticals INC | $14.19 | 2019 | |
| Abbvie INC. | $13.12 | 2023 | Vraylar |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $11.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Rizvi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.